February 23rd 2023
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
February 22nd 2023
Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.
February 21st 2023
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
February 16th 2023
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
February 9th 2023
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
December 22nd 2022
Virginia Kaklamani, MD reviews updated results and clinical implications of the phase 3 EMERALD trial evaluating elacestrant in patients with ER+/HER2- metastatic breast cancer presented at the 2022 San Antonio Breast Cancer Symposium.
December 19th 2022
Virginia G. Kaklamani, MD, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer.
September 2nd 2022
Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.
January 24th 2022
After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.
December 23rd 2021
Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.
October 28th 2021
Virginia Kaklamani, MD, DSc, presents results of the DESTINY-Breast03 clinical trial of trastuzumab deruxtecan compared with trastuzumab emtansine as treatment for patients with HER2-positive metastatic breast cancer.